Pfizer's $43B Seagen deal strengthens its oncology portfolio, offsets patent cliffs, and offers 70%+ upside potential. See ...

Pfizer is cutting costs, growing its core business, and trading at a deep discount despite looming patent losses and COVID ...

Pfizer Inc. (NYSE: PFE) announced today the completion of a global, ex-China, licensing agreement with 3SBio, Inc. (01530.HK) ...

Pfizer is positioning for a potential long-term rebound following a steep post-COVID revenue decline and a drop of over 50% ...

Schmeltz has headed Pfizer's global oncology business for the last year. Pfizer The breast-cancer drug had its first major data presentation just three years before its US approval in 2015, Pfizer ...

Previously, Dr. Boshoff oversaw clinical research and product development activities for Pfizer’s Oncology portfolio, including 24 approved innovative cancer medicines and biosimilars in more ...

Pfizer Inc. has completed the previously announced global, ex-China, licensing agreement with 3SBio Inc., which grants Pfizer exclusive rights for the development, manufacturing and commercialization ...

Pfizer has a new strategy for fighting cancer that could generate $5 billion a year. We got a look inside. Drug giant Merck just bought a biotech for $773 million, and it reveals the company's ...

Pfizer shifts oncology chief Schmeltz to new strategy role as rare disease head Varma fills in By Zoey Becker, Angus Liu Sep 2, 2022 11:18am Pfizer Andy Schmeltz rare diseases cancer drugs ...

Oncology will be a big part of that effort — Pfizer executives told investors earlier this year that they expect to have eight blockbuster cancer drugs by 2030, up from five now.

Pfizer Inc. today announced changes to its executive leadership team to further advance its aspirations to discover and develop new medicines and vaccines, with an emphasis on oncology. Under his ...